文献速递胃肠动力与功能性疾病

面对面催眠治疗与智能手机自助催眠治疗在肠易激综合征中的多中心三臂随机对照试验

In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial.
PubMed 文献 · Gut · 2026-07-25

这项多中心三臂非劣效性随机对照试验纳入230例肠易激综合征患者,比较12周面对面治疗师实施催眠、智能手机自助催眠与在线自助心理教育。主要终点为FDA腹痛应答率,面对面组48%、手机自助组33%、心理教育组22%,手机自助催眠未能证明非劣效于面对面催眠(-14.7%,95%CI -29.3%至0.9%)。

要点

  • 手机自助催眠未达到非劣效于面对面催眠的非劣效界值10%。
  • 面对面催眠在16周时优于心理教育(OR 3.48,95%CI 1.68-7.20,p<0.001)。
  • 两种催眠在6个月随访时均优于心理教育,心理症状组间无显著差异。

核心结论

  • 本研究未能证明智能手机自助催眠在减少腹痛方面非劣效于面对面治疗师实施催眠。
  • 但手机自助催眠显示出可观的应答率,提示其作为广泛适用且具成本效益替代方案的潜力。

研究设计与样本

  • 多中心、三臂、非劣效性随机对照试验,纳入符合Rome IV标准、16-75岁的肠易激综合征患者。
  • 患者随机分配至12周面对面治疗师实施催眠、智能手机自助催眠或在线自助心理教育。
  • 共230例患者被随机分配,平均年龄38.2±13.8岁,女性占70.4%。
  • 主要终点为FDA定义的腹痛应答(每周最严重日腹痛平均值较基线下降≥30%,且4周随访中至少2周达到)。
  • 非劣效界值为10%。

主要发现

  • FDA腹痛应答率:面对面催眠组48%,手机自助催眠组33%,心理教育组22%。
  • 手机自助催眠对比面对面催眠的差异为-14.7%(95%CI -29.3%至0.9%),未能证明非劣效。
  • 第16周时,面对面催眠优于心理教育(OR 3.48,95%CI 1.68至7.20,p<0.001)。
  • 6个月随访时,两种催眠均优于心理教育(手机自助催眠OR 3.11,95%CI 1.37至7.09,p=0.007;面对面催眠OR 4.68,95%CI 2.07至10.57,p<0.001)。
  • 组间心理症状变化无显著治疗效应。

关键数值与推荐

  • 主要终点腹痛应答定义:每周最严重日腹痛平均值较基线下降≥30%,且4周随访中至少2周达到。
  • 非劣效界值为10%。
  • 次要终点包括IBS症状严重度量表下降≥50分及心理症状变化。

临床怎么用

  • 面对面治疗师实施催眠仍是证据支持的有效选择,尤其在第16周时优于心理教育。
  • 智能手机自助催眠虽未证明非劣效,但应答率可观,可作为资源有限时的替代方案考虑。
  • 两种催眠在6个月随访时均显示优于心理教育的持续效果。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypnotherapy is an evidence-based therapy recommended for IBS, but access to therapist-led hypnotherapy is limited by costs and availability. OBJECTIVE: We studied the effectiveness of smartphone-based self-guided hypnotherapy versus in-person therapist-delivered hypnotherapy. DESIGN: This multicentre, three-armed non-inferiority randomised controlled trial (RCT) included patients with IBS (Rome IV, 16-75 years). Patients were randomised to 12-week in-person therapist-delivered hypnotherapy, smartphone-based self-guided hypnotherapy or online self-guided psychoeducation. The primary endpoint was abdominal pain response per Food and Drug Administration (FDA) definition (≥30% reduction from baseline in weekly average of worst daily abdominal pain in at least 2 out of 4 weeks follow-up). The non-inferiority margin was 10%. Secondary endpoints included ≥50 points IBS-symptom severity scale reduction and changes in psychological symptoms. RESULTS: A total of 230 patients (mean±SD age 38.2±13.8 years, 70.4% female) were randomised. FDA abdominal pain response rates were 48% for in-person therapist-delivered hypnotherapy, 33% for smartphone-based self-guided hypnotherapy and 22% for psychoeducation. Non-inferiority of online to in-person hypnotherapy could not be shown (-14.7%, 95% CI -29.3% to 0.9%). In-person hypnotherapy was more effective than psychoeducation (OR 3.48, 95% CI 1.68 to 7.20, p<0.001) at week 16, both hypnotherapy groups were more effective at 6-month follow-up (OR 3.11, 95% CI 1.37 to 7.09, p=0.007 and OR 4.68, 95% CI 2.07 to 10.57, p<0.001). There were no significant treatment effects on psychological symptoms between groups. CONCLUSION: This multicentre RCT could not demonstrate non-inferiority of smartphone-based self-guided hypnotherapy compared with in-person therapist-delivered hypnotherapy in reducing abdominal pain. However, substantial response rates for smartphone-based self-guided hypnotherapy highlight its potential as a broadly applicable and cost-effective alternative. TRIAL REGISTRATION NUMBER: NCT03899779.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Snijkers JTW, Bosman MHMA, Winkens B, et al. In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial. Gut. 2026. PMID: 42502003. doi:10.1136/gutjnl-2026-338385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。